Novo Nordisk's leadership shakeup as controlling shareholder pushes for changes to revive growth amid competition from Eli Lilly's drugs.
Investor Tom Hulick highlights Broadcom's AI-focused, power-efficient ASICs and Eli Lilly's GLP-1 drug pipeline, while StockStory cautions against uncritical acceptance of Wall Street price targets.
Former teacher testifies in $40M lawsuit over student's shooting, recounting life-threatening injuries and alleging school ignored warnings.
Novo Nordisk's leadership shakeup as controlling shareholder pushes for changes to revive growth amid competition from Eli Lilly's drugs.
Investor Tom Hulick highlights Broadcom's AI-focused, power-efficient ASICs and Eli Lilly's GLP-1 drug pipeline, while StockStory cautions against uncritical acceptance of Wall Street price targets.
Former teacher testifies in $40M lawsuit over student's shooting, recounting life-threatening injuries and alleging school ignored warnings.